Zobrazeno 1 - 10
of 153
pro vyhledávání: ''
Autor:
José Manuel Mas, Carmen Montoto, Andrea Naves, Baldomero Oliva, Alonso Fernández-Nistal, Araceli López, Cristina Segú-Vergés, Enric Carcereny, Guillem Jorba, Mireia Coma
Publikováno v:
Oncotarget
Around 3–7% of patients with non-small cell lung cancer (NSCLC), which represent 85% of diagnosed lung cancers, have a rearrangement in the ALK gene that produces an abnormal activity of the ALK protein cell signaling pathway. The developed ALK tyr
Autor:
Ferdinando Riccardi, Bruno Chiurazzi, Raffaella Ruocco, Francesca Ambrosio, Maria Fiorella Brangi, Carmela Barbato, Vincenzo Di Lauro, Dario Arundine, M. Biglietto, Roberto Fiorentino, Francesco Jacopo Romano, Maresa Cammarota, Sarah Scagliarini, Livio Puglia, Ivana Cerillo, Carmen Mocerino
Publikováno v:
Oncotarget
The stock of therapeutic weapons available in metastatic colorectal cancer (mCRC) has been progressively grown over the years, with improving both survival and patients' clinical outcome: notwithstanding advances in the knowledge of mCRC biology, as
Autor:
Juliann E. Kosovec, Laila Babar, Shahin Ayazi, Gene Grant Finley, Ali H. Zaidi, Soyoung Lee, Blair A. Jobe, Ashten N. Omstead, Madison Salvitti, Ronan J. Kelly, Ping Zheng, Ajay Goel, Anastasia Gorbunova
Publikováno v:
Oncotarget
Background: Esophageal adenocarcinoma (EAC) is a deadly disease with limited treatment options. STING is a transmembrane protein that activates transcription of interferon genes, resulting in stimulation of APCs and enhanced CD8+ T-cell infiltration.
Publikováno v:
Oncotarget
Introduction: Endocrine therapy has played an important role in the management of ER positive breast cancer over recent decades. Despite this, not all patients respond equally to endocrine intervention, which can lead to resistance, associated diseas
Autor:
Neelakshi Mungra, Guillaume Vignaux, Jean Engohang-Ndong, Eden Padayachee, Jean De La Croix Ndong, Fleury Augustin Nsole Biteghe, Stefan Barth, Nyangone Ekome Toung Chalomie, Krupa Naran
Publikováno v:
Oncotarget
The epidermal growth factor receptor (EGFR) has been recognized as an important therapeutic target in oncology. It is commonly overexpressed in a variety of solid tumors and is critically involved in cell survival, proliferation, metastasis, and angi
Autor:
Changchun Deng, Kelly Zullo, Cristina Kinahan, Susan E. Bates, Ahmed Sawas, Xavier O. Jirau Serrano, Luigi Scotto, Owen A. O'Connor
Publikováno v:
Oncotarget
The antiproliferative effect induced by histone deactylase inhibitors (HDACi) is associated with the up-regulated expression of the cyclin-dependent kinase inhibitor p21. Paradoxically, the increased expression of p21 correlates with a reduced cell k
Publikováno v:
Oncotarget
Topical glucocorticoids, well-known anti-inflammatory drugs, induce multiple adverse effects, including skin atrophy. The sex-specific effects of systemic glucocorticoids are known, but sexual dimorphism of therapeutic and side effects of topical ste
Autor:
Junya Fujimoto, Keisuke Ishimatsu, Roswitha Pfragner, Rahul Telange, Chunfeng Tan, Stefan Zahler, Shuaijun Wang, Karine Pozo, James A. Bibb, Angela M. Carter, Elizabeth G. Grubbs, Masaya Takahashi, Sarah C. Oltmann
Publikováno v:
Oncotarget
Medullary thyroid carcinoma (MTC) is a slow growing neuroendocrine (NE) tumor for which few treatment options are available. Its incidence is rising and mortality rates have remained unchanged for decades. Increasing the repertoire of available treat
Autor:
Tatsuzo Mizukami, Nozomi Kobayashi, Yuki Fujii, Fumihiko Matsuzawa, Futoshi Kawamata, Hirofumi Kamachi, Takahiro Einama, Akinobu Taketomi, Yutaka Hatanaka
Publikováno v:
Oncotarget
Pancreatic cancer often has a very poor prognosis, even after complete resection. The recurrence of hepatic and peritoneal metastases is an important prognostic factor; therefore, the development of improved adjuvant therapy is urgently required. Mes
Autor:
Mark J. Levis, Bao Nguyen, Donald Small, Tessa Seale, Kozo Nagai, Courtney M. Shirley, Amy S. Duffield, Lihong Hou, Gabriel Ghiaur, Hayley S Ma, Li Li
Publikováno v:
Oncotarget. 9:32885-32899
Acute myeloid leukemia (AML) patients with FLT3/ITD mutations have a poor prognosis. Monotherapy with selective FLT3 tyrosine kinase inhibitors (TKIs) have shown transient and limited efficacy due to the development of resistance. Arsenic trioxide (A